Creating a vaccine to prevent Staph Aureus infections
Official title: Development of a Staph Aureus Vaccine
Funded at Biological Mimetics, INC. · NIH-10932152 · Data updated 2026-11-12
This study is working on a new vaccine to help protect people from MRSA, a tough infection often caught in hospitals, and they're testing different versions in animals to find the best one that boosts the immune system to fight off this infection.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biological Mimetics, INC. NIH-funded |
| Lab location | 1 site (Frederick, United States) |
| Project start | September 20, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $296,442 |
| NIH project number | 5R43AI174497-02 |
| Project ID | NIH-10932152 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for MRSA infections, such as patients undergoing surgery or those with weakened immune systems.
✕Less likely to help
Patients who are not at risk for MRSA infections or those who have already been infected may not benefit from this research.
What this research studies
This research focuses on developing a vaccine to protect against Methicillin-resistant Staphylococcus aureus (MRSA), a common and dangerous hospital-acquired infection. The researchers will use innovative methods to create and test various vaccine candidates in animal models, specifically looking at how well these candidates stimulate the immune system to fight off infections. By comparing different vaccine formulations, the goal is to identify the most effective candidate for further development and eventual human trials.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of MRSA infections, improving patient outcomes and reducing healthcare costs.
How similar studies have gone: Previous research has shown promise in developing vaccines against antibiotic-resistant bacteria, indicating that this approach has potential for success.
Where this research is happening
-
Biological Mimetics, INC.
Frederick, United States Active
Researchers
- Principal investigator: Dollery, Stephen Jeffrey — Biological Mimetics, INC.
- Study coordinator: Dollery, Stephen Jeffrey
Related research
Other NIH-funded projects on the same topics.
-
Vaccine candidate to prevent infections from Acinetobacter baumannii
A small SBIR project is developing a new vaccine to protect people from dangerous Acinetobacter baumannii infections.
-
A simple, machine-free malaria test
A quick, low-cost CRISPR-based malaria test that people in low-resource areas can run without lab equipment or advanced training.
-
Developing a vaccine to protect against antibiotic-resistant Acinetobacter baumannii infections
This study is working on a new vaccine to help protect people from tough infections caused by a bacteria called Multi-Drug Resistant Acinetobacter baumannii, which is a big concern in hospitals.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.